bupivacaine hydrochloride injection, USP - SPINAL Highlights

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use BUPIVACAINE SPINAL safely and effectively. See full prescribing information for BUPIVACAINE SPINAL.
 
BUPIVACAINE SPINAL (bupivacaine hydrochloride in dextrose injection) for subarachnoid injection
Initial U.S. Approval: 1984

INDICATIONS AND USAGE

BUPIVACAINE SPINAL is an amide-local anesthetic indicated in adults for subarachnoid injection for the production of subarachnoid block (spinal anesthesia). (1)

DOSAGE AND ADMINISTRATION

The dosage of BUPIVACAINE SPINAL administered varies with the anesthetic procedure, the vascularity of the tissues, the number of neuronal segments to be blocked, the depth of anesthesia and degree of muscle relaxation required, the duration of anesthesia desired, individual tolerance, and the physical condition of the patient. Administer the smallest dosage and concentration required to produce the desired result. The following are general dosage guidelines:

BUPIVACAINE SPINAL 6 mg is generally adequate for vaginal delivery. (2.2)
BUPIVACAINE SPINAL 7.5 mg is generally adequate for spinal anesthesia for lower extremity and perineal procedures. (2.2)
BUPIVACAINE SPINAL 12 mg is generally adequate for lower abdominal procedures. (2.2)
BUPIVACAINE SPINAL 7.5 mg to 10.5 mg is generally adequate for Cesarean section. (2.2)

DOSAGE FORMS AND STRENGTHS

Injection: 15 mg/2 mL (7.5 mg/mL) in single-dose glass ampules. (3)

CONTRAINDICATIONS

Intravenous regional anesthesia (Bier Block). (4)
Septicemia. (4)
Severe hemorrhage, severe hypotension or shock, and arrhythmias, such as complete heartblock, which severely reduce cardiac output. (4)
Known hypersensitivity to bupivacaine or to any local anesthetic agent of the amide-type or to other components of BUPIVACAINE SPINAL. (4)
Local infection at the site of proposed lumbar puncture. (4)

WARNINGS AND PRECAUTIONS

Use of Spinal Anesthetics During Uterine Contractions: Spinal anesthetics, including BUPIVACAINE SPINAL, should not be injected during uterine contractions because cerebrospinal fluid current may carry the drug further cephalad than desired, resulting in a high motor block. (5.1)
Patients with Hypertension: Sympathetic blockade due to spinal anesthesia may result in peripheral vasodilation and hypotension. Monitor blood pressure frequently. Hypotension may be controlled by administration of vasoconstrictor agents in titrated dosages depending on the severity of hypotension and response to treatment. Monitor the onset of adequate spinal anesthesia frequently. (5.2)
Dose-Related Toxicity: Monitor cardiovascular and respiratory vital signs and patient’s state of consciousness after injection of BUPIVACAINE SPINAL. (5.3)
Risk of Systemic Toxicities with Unintended Intravascular Injection: Unintended intravascular injection may be associated with systemic toxicities, including CNS or cardiorespiratory depression and coma, progressing ultimately to respiratory arrest. Aspirate for blood and cerebrospinal fluid (where applicable) prior to each dose. (5.4)
Methemoglobinemia: Cases of methemoglobinemia have been reported in association with local anesthetic use. See full prescribing information for more detail on managing these risks. (5.5)
Risk of Cardiac Arrest with Use of Epidural Bupivacaine in Obstetrical Anesthesia: There have been reports of cardiac arrest during use of bupivacaine hydrochloride 0.75% solution for epidural anesthesia in obstetrical patients. BUPIVACAINE SPINAL (bupivacaine hydrochloride in dextrose injection) is recommended for spinal anesthesia in obstetrical patients. (5.6)
Chondrolysis with Intra-Articular Infusion: Intra-articular infusions of local anesthetics including bupivacaine following arthroscopic and other surgical procedures is an unapproved use, and there have been post‑marketing reports of chondrolysis in patients receiving such infusions. (5.7)
Risk of Cardiac Arrest with Intravenous Regional Anesthesia Use (Bier Block): There have been reports of cardiac arrest and death during the use of bupivacaine for intravenous regional anesthesia (Bier Block). (5.8)

ADVERSE REACTIONS

Most common adverse reactions are hypotension due to loss of sympathetic tone, and diaphragmatic paralysis or hypoventilation due to cephalad spread and high motor block. (6)

 

To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1‑800‑438‑1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

Local Anesthetics: The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered. (7.1)
Drugs Associated with Methemoglobinemia: Patients are at increased risk of developing methemoglobinemia when concurrently exposed to nitrates, nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, and other drugs. (7.2)

USE IN SPECIFIC POPULATIONS

Pediatric Use: Administration of BUPIVACAINE SPINAL in patients younger than 18 years is not recommended. (8.4)
Geriatric Use: Patients 65 years and over, particularly those with hypertension, may be at increased risk for developing hypotension while undergoing spinal anesthesia with BUPIVACAINE SPINAL. (8.5)
Moderate to Severe Hepatic Impairment: Consider increased monitoring for bupivacaine systemic toxicity. (8.6)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 12/2022

Find bupivacaine hydrochloride injection, USP - SPINAL medical information:

Find bupivacaine hydrochloride injection, USP - SPINAL medical information:

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

bupivacaine hydrochloride injection, USP - SPINAL Quick Finder

Prescribing Information
Download Prescribing Information

Health Professional Information

Highlights

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use BUPIVACAINE SPINAL safely and effectively. See full prescribing information for BUPIVACAINE SPINAL.
 
BUPIVACAINE SPINAL (bupivacaine hydrochloride in dextrose injection) for subarachnoid injection
Initial U.S. Approval: 1984

INDICATIONS AND USAGE

BUPIVACAINE SPINAL is an amide-local anesthetic indicated in adults for subarachnoid injection for the production of subarachnoid block (spinal anesthesia). (1)

DOSAGE AND ADMINISTRATION

The dosage of BUPIVACAINE SPINAL administered varies with the anesthetic procedure, the vascularity of the tissues, the number of neuronal segments to be blocked, the depth of anesthesia and degree of muscle relaxation required, the duration of anesthesia desired, individual tolerance, and the physical condition of the patient. Administer the smallest dosage and concentration required to produce the desired result. The following are general dosage guidelines:

BUPIVACAINE SPINAL 6 mg is generally adequate for vaginal delivery. (2.2)
BUPIVACAINE SPINAL 7.5 mg is generally adequate for spinal anesthesia for lower extremity and perineal procedures. (2.2)
BUPIVACAINE SPINAL 12 mg is generally adequate for lower abdominal procedures. (2.2)
BUPIVACAINE SPINAL 7.5 mg to 10.5 mg is generally adequate for Cesarean section. (2.2)

DOSAGE FORMS AND STRENGTHS

Injection: 15 mg/2 mL (7.5 mg/mL) in single-dose glass ampules. (3)

CONTRAINDICATIONS

Intravenous regional anesthesia (Bier Block). (4)
Septicemia. (4)
Severe hemorrhage, severe hypotension or shock, and arrhythmias, such as complete heartblock, which severely reduce cardiac output. (4)
Known hypersensitivity to bupivacaine or to any local anesthetic agent of the amide-type or to other components of BUPIVACAINE SPINAL. (4)
Local infection at the site of proposed lumbar puncture. (4)

WARNINGS AND PRECAUTIONS

Use of Spinal Anesthetics During Uterine Contractions: Spinal anesthetics, including BUPIVACAINE SPINAL, should not be injected during uterine contractions because cerebrospinal fluid current may carry the drug further cephalad than desired, resulting in a high motor block. (5.1)
Patients with Hypertension: Sympathetic blockade due to spinal anesthesia may result in peripheral vasodilation and hypotension. Monitor blood pressure frequently. Hypotension may be controlled by administration of vasoconstrictor agents in titrated dosages depending on the severity of hypotension and response to treatment. Monitor the onset of adequate spinal anesthesia frequently. (5.2)
Dose-Related Toxicity: Monitor cardiovascular and respiratory vital signs and patient’s state of consciousness after injection of BUPIVACAINE SPINAL. (5.3)
Risk of Systemic Toxicities with Unintended Intravascular Injection: Unintended intravascular injection may be associated with systemic toxicities, including CNS or cardiorespiratory depression and coma, progressing ultimately to respiratory arrest. Aspirate for blood and cerebrospinal fluid (where applicable) prior to each dose. (5.4)
Methemoglobinemia: Cases of methemoglobinemia have been reported in association with local anesthetic use. See full prescribing information for more detail on managing these risks. (5.5)
Risk of Cardiac Arrest with Use of Epidural Bupivacaine in Obstetrical Anesthesia: There have been reports of cardiac arrest during use of bupivacaine hydrochloride 0.75% solution for epidural anesthesia in obstetrical patients. BUPIVACAINE SPINAL (bupivacaine hydrochloride in dextrose injection) is recommended for spinal anesthesia in obstetrical patients. (5.6)
Chondrolysis with Intra-Articular Infusion: Intra-articular infusions of local anesthetics including bupivacaine following arthroscopic and other surgical procedures is an unapproved use, and there have been post‑marketing reports of chondrolysis in patients receiving such infusions. (5.7)
Risk of Cardiac Arrest with Intravenous Regional Anesthesia Use (Bier Block): There have been reports of cardiac arrest and death during the use of bupivacaine for intravenous regional anesthesia (Bier Block). (5.8)

ADVERSE REACTIONS

Most common adverse reactions are hypotension due to loss of sympathetic tone, and diaphragmatic paralysis or hypoventilation due to cephalad spread and high motor block. (6)

 

To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1‑800‑438‑1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

Local Anesthetics: The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered. (7.1)
Drugs Associated with Methemoglobinemia: Patients are at increased risk of developing methemoglobinemia when concurrently exposed to nitrates, nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, and other drugs. (7.2)

USE IN SPECIFIC POPULATIONS

Pediatric Use: Administration of BUPIVACAINE SPINAL in patients younger than 18 years is not recommended. (8.4)
Geriatric Use: Patients 65 years and over, particularly those with hypertension, may be at increased risk for developing hypotension while undergoing spinal anesthesia with BUPIVACAINE SPINAL. (8.5)
Moderate to Severe Hepatic Impairment: Consider increased monitoring for bupivacaine systemic toxicity. (8.6)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 12/2022

Medication Guide

Health Professional Information

{{section_name_patient}}

{{section_body_html_patient}}

Resources

Didn’t find what you were looking for? Contact us.

MI Digital Assistant

Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.

Call 800-438-1985*

*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.

Medical Inquiry

Submit a medical question for Pfizer prescription products.

Report Adverse Event

Pfizer Safety

To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:

Pfizer Safety Reporting Site

*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.

If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.

FDA Medwatch

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.